Ovarian serous carcinoma: Recent concepts on its origin and carcinogenesis

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Li, Jie ^a,b   Fadare, Oluwole ^c   Xiang, Li ^a,b   Kong, Beihua ^a,b   Zheng, Wenxin ^a,b,d  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Carcinogenesis; Fallopian tube; Ovarian cancer; p53 signatures; Serous carcinoma

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; PROTEIN P53;

CANCER CLASSIFICATION; CANCER GRADING; CARCINOGENESIS; DISEASE SEVERITY; HISTOGENESIS; HUMAN; IMMUNOREACTIVITY; MIXED MULLERIAN TUMOR; MOLECULAR GENETICS; NONHUMAN; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; PHENOTYPE; PLASTICITY; REVIEW; SALPINGOOOPHORECTOMY; UTERINE TUBE; ANIMAL; CELL TRANSFORMATION; CYSTADENOCARCINOMA; FEMALE; GENETICS; OVARY TUMOR; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 84862804745     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-8     Document Type: Review

References (88)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Cancer statistics, 2008. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
3. Epithelial ovarian cancer: prevention, diagnosis, and treatment. Partridge EE, Barnes MN, CA Cancer J Clin 1999 49 297 320 10.3322/canjclin.49.5. 297 11198956
4. SEER cancer statistics review, 1975-2004. Bethesda, Md.: National Cancer Institute, Ries LA, Melbert D, Krapcho M, et al, 2007
5. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM, Int J Gynecol Pathol 2004 23 41 44 10.1097/01.pgp. 0000101080.35393.16 14668549 (Pubitemid 38018236)
6. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Selvaggi SM, Arch Pathol Lab Med 2000 124 477 10705419
7. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B, Am J Surg Pathol 2001 25 1283 1289 10.1097/00000478-200110000- 00009 11688463 (Pubitemid 32917122)
8. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. Powell CB, Kenley E, Chen LM, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M, Ziegler J, J Clin Oncol 2005 23 127 132 15625367 (Pubitemid 41702631)
9. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW, Crum CP, Am J Surg Pathol 2006 30 230 236 10.1097/01.pas.0000180854.28831.77 16434898 (Pubitemid 43740193)
10. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, et al. J Pathol 2007 211 26 35 10.1002/path.2091 17117391 (Pubitemid 46092026)
11. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Mehrad M, Ning G, Chen EY, Mehra KK, Crum CP, Adv Anat Pathol 2010 17 293 302 10.1097/PAP.0b013e3181ecdee1 20733351
12. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Kurman RJ, Shih Ie M, Hum Pathol 2011 42 918 931 10.1016/j.humpath.2011.03.003 21683865
13. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M, Cancer Res 2004 64 6915 6918 10.1158/0008-5472.CAN-04-2067 15466181 (Pubitemid 39330999)
14. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways. Korner M, Burckhardt E, Mazzucchelli L, J Pathol 2005 207 20 26 10.1002/path.1817 16021676 (Pubitemid 41200710)
15. Grading ovarian serous carcinoma using a two-tier system. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG, Am J Surg Pathol 2004 28 496 504 10.1097/00000478-200404000-00009 15087669 (Pubitemid 38436523)
16. Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G, Tan OL, Mol Cell Endocrinol 2006 247 4 21 10.1016/j.mce.2005.09.014 16297528 (Pubitemid 43277703)
17. Ovarian surface epithelium: biology, endocrinology, and pathology. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC, Endocr Rev 2001 22 255 288 10.1210/er.22.2.255 11294827 (Pubitemid 32458162)
18. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Cheng W, Liu J, Yoshida H, Rosen D, Naora H, Nat Med 2005 11 531 537 10.1038/nm1230 15821746 (Pubitemid 40685976)
19. Developmental patterning in the wrong context: the paradox of epithelial ovarian cancers. Naora H, Cell Cycle 2005 4 1033 1035 10.4161/cc.4.8.1906 16082202 (Pubitemid 41365358)
20. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Bowen NJ, Logani S, Dickerson EB, Kapa LB, Akhtar M, Benigno BB, McDonald JF, Gynecol Oncol 2007 104 331 337 10.1016/j.ygyno.2006.08.052 17064757 (Pubitemid 46135661)
21. Extraovarian primary peritoneal papillary serous carcinoma. Bhuyan P, Mahapatra S, Sethy S, Parida P, Satpathy S, Arch Gynecol Obstet 2010 281 561 564 10.1007/s00404-009-1201-2 19693524
22. Multiple focal extraovarian serous carcinoma. August CZ, Murad TM, Newton M, Int J Gynecol Pathol 1985 4 11 23 10.1097/00004347-198501000-00002 3880151 (Pubitemid 15149954)
23. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Dalrymple JC, Bannatyne P, Russell P, Solomon HJ, Tattersall MH, Atkinson K, Carter J, Duval P, Elliott P, Friedlander M, et al. Cancer 1989 64 110 115 10.1002/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0. CO;2-5 2731107 (Pubitemid 19167146)
24. The secondary Mullerian system. Lauchlan SC, Obstet Gynecol Surv 1972 27 133 146 10.1097/00006254-197203000-00001 4614139
25. Initial endometriosis showing direct morphologic evidence of metaplasia in the pathogenesis of ovarian endometriosis. Zheng W, Li N, Wang J, Ulukus EC, Ulukus M, Arici A, Liang SX, Int J Gynecol Pathol 2005 24 164 172 10.1097/01.RCT.0000157091.37057.B4 15782073 (Pubitemid 40389541)
26. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y, Clin Med Res 2007 5 35 44 10.3121/cmr.2007.702 17456833 (Pubitemid 350218778)
27. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. Levanon K, Crum C, Drapkin R, J Clin Oncol 2008 26 5284 5293 10.1200/JCO.2008.18.1107 18854563
28. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, et al. Am J Surg Pathol 2007 31 161 169 10.1097/01.pas.0000213335.40358.47 17255760 (Pubitemid 46175016)
29. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP, J Clin Oncol 2008 26 4160 4165 10.1200/JCO.2008.16.4814 18757330
30. Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Crum CP, Mol Oncol 2009 3 165 170 10.1016/j.molonc.2009.01.004 19383378
31. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH, J Pathol 2001 195 451 456 10.1002/path.1000 11745677 (Pubitemid 33069670)
32. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ, Gynecol Oncol 2006 100 58 64 10.1016/j.ygyno.2005.06.065 16137750 (Pubitemid 41815050)
33. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P, Gynecol Oncol 2002 87 52 56 10.1006/gyno.2002.6779 12468342 (Pubitemid 36027101)
34. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM, Am J Obstet Gynecol 2006 194 1702 1709 10.1016/j.ajog.2006.03.006 16731090 (Pubitemid 43766909)
35. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ, Br J Cancer 2004 90 1492 1497 10.1038/sj.bjc.6601692 15083174 (Pubitemid 38648227)
36. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG, J Clin Oncol 2007 25 3985 3990 10.1200/JCO.2007.12.2622 17761984 (Pubitemid 47477278)
37. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Hermsen BB, van Diest PJ, Berkhof J, Menko FH, Gille JJ, Piek JM, Meijer S, Winters HA, Kenemans P, Mensdorff-Pouilly S, Verheijen RH, Int J Cancer 2006 119 1412 1418 10.1002/ijc.21988 16615107 (Pubitemid 44258819)
38. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, et al. JAMA 2006 296 185 192 10.1001/jama.296.2.185 16835424 (Pubitemid 44050372)
39. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Salvador S, Rempel A, Soslow RA, Gilks B, Huntsman D, Miller D, Gynecol Oncol 2008 110 408 417 10.1016/j.ygyno.2008.05.010 18597838
40. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R, Am J Surg Pathol 2010 34 1407 1416 10.1097/PAS.0b013e3181ef7b16 20861711
41. Low-grade ovarian serous neoplasms (Low-Grade Serous Carcinoma and Serous Borderline Tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Boyd C, McCluggage WG, Am J Surg Pathol 2012 36 368 375 10.1097/PAS.0b013e31823732a9 22082603
42. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R, Kurman RJ, Logani S, Shih Ie M, Am J Surg Pathol 2007 31 1007 1012 10.1097/PAS. 0b013e31802cbbe9 17592266 (Pubitemid 47012296)
43. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ, Shih Ie M, Am J Surg Pathol 2010 34 433 443 10.1097/PAS.0b013e3181cf3d79 20154587
44. Tubal ligation and risk of ovarian cancer. Piek JM, van Diest PJ, Zweemer RP, Kenemans P, Verheijen RH, Lancet 2001 358 844 11570411
45. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, Drapkin R, Oncogene 2010 29 1103 1113 10.1038/onc.2009.402 19935705
46. Genetic analysis of the early natural history of epithelial ovarian carcinoma. Pothuri B, Leitao MM, Levine DA, Viale A, Olshen AB, Arroyo C, Bogomolniy F, Olvera N, Lin O, Soslow RA, et al. PLoS One 2010 5 10358 10.1371/journal.pone.0010358 20436685
47. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP, Gynecol Oncol 2008 109 168 173 10.1016/j.ygyno.2008.01.012 18342932
48. PAX2-null secretory cell outgrowths in the oviduct and their relationship to pelvic serous cancer. Quick CM, Ning G, Bijron J, Laury A, Wei TS, Chen EY, Vargas SO, Betensky RA, McKeon FD, Xian W, Crum CP, Mod Pathol 2011 25 455
49. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, Monte N, Quade BJ, McKeon FD, Yassin Y, et al. J Pathol 2010 222 110 116 20597068
50. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Salani R, Kurman RJ, Giuntoli R, Gardner G, Bristow R, Wang TL, Shih IM, Int J Gynecol Cancer 2008 18 487 491 10.1111/j.1525-1438.2007.01039.x 17692090 (Pubitemid 351668307)
51. A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Senturk E, Cohen S, Dottino PR, Martignetti JA, Gynecol Oncol 2010 119 376 383 10.1016/j.ygyno.2010.07.026 20797776
52. Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Tone AA, Begley H, Sharma M, Murphy J, Rosen B, Brown TJ, Shaw PA, Clin Cancer Res 2008 14 4067 4078 10.1158/1078-0432.CCR-07-4959 18593983
53. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, et al. Clin Cancer Res 2005 11 6116 6126 10.1158/1078-0432.CCR-04-2509 16144910 (Pubitemid 41262937)
54. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Shih Ie M, Kurman RJ, Am J Pathol 2004 164 1511 1518 10.1016/S0002-9440(10)63708-X 15111296 (Pubitemid 38529752)
55. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Kurman RJ, ShihIe M, Am J Surg Pathol 2011 34 433 443
56. Tubal origin of 'ovarian' low-grade serous carcinoma. Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, Kong B, Zheng W, Mod Pathol 2011 24 1488 1499 10.1038/modpathol.2011.106 21701538
57. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Kurman RJ, Vang R, Junge J, Hannibal CG, Kjaer SK, Shih Ie M, Am J Surg Pathol 2011 35 1605 1614 10.1097/PAS.0b013e318229449f 21997682
58. Fallopian tube correlates of ovarian serous borderline tumors. Laury AR, Ning G, Quick CM, Bijron J, Parast MM, Betensky RA, Vargas SO, McKeon FD, Xian W, Nucci MR, Crum CP, Am J Surg Pathol 2011 35 1759 1765 10.1097/PAS. 0b013e318233b0f7 22089527
59. Pathology of ovarian cancer precursors. Scully RE, J Cell Biochem Suppl 1995 23 208 218 8747398 (Pubitemid 26032877)
60. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Smith Sehdev AE, Sehdev PS, Kurman RJ, Am J Surg Pathol 2003 27 725 736 10.1097/00000478-200306000-00003 12766576 (Pubitemid 36617509)
61. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Burks RT, Sherman ME, Kurman RJ, Am J Surg Pathol 1996 20 1319 1330 10.1097/00000478-199611000-00003 8898836 (Pubitemid 26367203)
62. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion. McKenney JK, Balzer BL, Longacre TA, Am J Surg Pathol 2006 30 1209 1221 10.1097/01.pas.0000213299.11649.fa 17001150 (Pubitemid 44454698)
63. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Seidman JD, Soslow RA, Vang R, Berman JJ, Stoler MH, Sherman ME, Oliva E, Kajdacsy-Balla A, Berman DM, Copeland LJ, Hum Pathol 2004 35 918 933 10.1016/j.humpath.2004.03.004 15297960 (Pubitemid 39037176)
64. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ, Hum Pathol 2004 35 934 948 10.1016/j.humpath.2004.03.005 15297961 (Pubitemid 39037177)
65. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (or = 5-year) follow-up. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR, Am J Surg Pathol 2005 29 707 723 10.1097/01.pas.0000164030.82810.db 15897738 (Pubitemid 40734421)
66. The cell of origin of ovarian epithelial tumours. Dubeau L, Lancet Oncol 2008 9 1191 1197 10.1016/S1470-2045(08)70308-5 19038766
67. Integrated genomic analyses of ovarian carcinoma. Nature CGARN, Nature 2011 474 609 615 10.1038/nature10166 21720365
68. The emerging role of the distal Fallopian tube and p53 in pelvic serous carcinogenesis. Herrington CS, McCluggage WG, J Pathol 2010 220 5 6 10.1002/path.2630 19882674
69. The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube. Xian W, Miron A, Roh M, Semmel DR, Yassin Y, Garber J, Oliva E, Goodman A, Mehra K, Berkowitz RS, et al. J Pathol 2010 220 17 23 10.1002/path.2624 19834951
70. Cancer susceptibility and the functions of BRCA1 and BRCA2. Venkitaraman AR, Cell 2002 108 171 182 10.1016/S0092-8674(02)00615-3 11832208 (Pubitemid 34161138)
71. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA, J Natl Cancer Inst 2006 98 1694 1706 10.1093/jnci/djj465 17148771 (Pubitemid 44942707)
72. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53. Werness BA, Parvatiyar P, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, DiCioccio RA, Wiest J, Tsukada Y, Ponder BA, Piver MS, J Natl Cancer Inst 2000 92 1088 1091 10.1093/jnci/92.13. 1088 10880552 (Pubitemid 30616483)
73. Genetic analysis of ovarian carcinoma histogenesis (Abstract). Palmieri M, LeiItao M, Baergen R, et al. Gynecol Oncol 2001 80 277
74. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Norquist BM, Garcia RL, Allison KH, Jokinen CH, Kernochan LE, Pizzi CC, Barrow BJ, Goff BA, Swisher EM, Cancer 2010 116 5261 5271 10.1002/cncr.25439 20665887
75. Diverse tumorigenic pathways in ovarian serous carcinoma. Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M, Am J Pathol 2002 160 1223 1228 10.1016/S0002-9440(10)62549-7 11943707 (Pubitemid 34411626)
76. Amplicon profiles in ovarian serous carcinomas. Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih Ie M, Wang TL, Int J Cancer 2007 120 2613 2617 10.1002/ijc.22609 17351921 (Pubitemid 46651282)
77. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih Ie M, Wang TL, Cancer Res 2009 69 4036 4042 19383911
78. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Singer G, Oldt R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M, J Natl Cancer Inst 2003 95 484 486 10.1093/jnci/95.6.484 12644542 (Pubitemid 36432423)
79. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih Ie M, Cancer Biol Ther 2006 5 779 785 10.4161/cbt.5.7.2751 16721043 (Pubitemid 44775134)
80. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, et al. J Pathol 2004 202 336 340 10.1002/path.1521 14991899 (Pubitemid 38325243)
81. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE, Nature 2002 418 934 10.1038/418934a 12198537 (Pubitemid 34976022)
82. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas. Staebler A, Heselmeyer-Haddad K, Bell K, Riopel M, Perlman E, Ried T, Kurman RJ, Hum Pathol 2002 33 47 59 10.1053/hupa.2002.30212 11823973 (Pubitemid 34112952)
83. K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary. Alvarez AA, Moore WF, Robboy SJ, Bentley RC, Gumbs C, Futreal PA, Berchuck A, Gynecol Oncol 2001 80 201 206 10.1006/gyno.2000.6066 11161860 (Pubitemid 32158459)
84. In serous ovarian neoplasms the frequency of Ki-ras mutations correlates with their malignant potential. Haas CJ, Diebold J, Hirschmann A, Rohrbach H, Lohrs U, Virchows Arch 1999 434 117 120 10.1007/s004280050314 10071245 (Pubitemid 29184988)
85. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Mayr D, Hirschmann A, Lohrs U, Diebold J, Gynecol Oncol 2006 103 883 887 10.1016/j.ygyno.2006.05.029 16806438 (Pubitemid 44821309)
86. Results from four rounds of ovarian cancer screening in a randomized trial. Partridge E, Kreimer AR, Greenlee RT, Williams C, Xu JL, Church TR, Kessel B, Johnson CC, Weissfeld JL, Isaacs C, et al. Obstet Gynecol 2009 113 775 782 19305319
87. Ovarian cancer immunotherapy: opportunities, progresses and challenges. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z, J Hematol Oncol 2010 3 7 10.1186/1756-8722-3-7 20146807
88. Total salpingectomy during abdominal hysterectomy: effects on ovarian reserve and ovarian stromal blood flow. Sezik M, Ozkaya O, Demir F, Sezik HT, Kaya H, J Obstet Gynaecol Res 2007 33 863 869 10.1111/j.1447-0756.2007.00669.x 18001455 (Pubitemid 350086521)